编者按“自古逢秋悲寂寥，我言秋日胜春朝”，2024年11月15-19日（美国西部时间），我们将迎来全球肝脏疾病研究的饕餮盛宴——第75届美国肝脏研究学会（AASLD）年会。值此盛会之际，全球首个获批治疗2型糖尿病（T2DM）的PPAR全激动剂西格列他 ...

Tempest Therapeutics (NASDAQ:TPST) shares dropped Thursday after the company updated data from an ongoing trial designed to test its PPAR⍺ antagonist, amezalpat (TPST-1120), as a first-line ...

This study concludes that activation of the PPARβ/δ-AMPK pathway is an effective strategy to slow the development of liver ...

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic ...